Transdermal estrogen replacement therapy: Beneficial effects on hemostatic risk factors for cardiovascular disease

Maturitas

Volumn 24, Issue 1-2, 1996, Pages 43-50

  Lindoff, Claes ^a   Peterson, Fredrik ^b   Lecander, Ingegerd ^a   Martinsson, Gunilla ^a   Åstedt, Birger ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b HALMSTAD HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Coagulation; Estrogen; Fibrinolysis; Postmenopause

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; ESTRADIOL; ESTROGEN; FIBRINOGEN; MEDROXYPROGESTERONE ACETATE; PLASMA PROTEIN; PROTEIN C; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; HEART PROTECTION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; SKIN IRRITATION; THROMBOEMBOLISM; THROMBOSIS; TRANSDERMAL DRUG ADMINISTRATION; VAGINA BLEEDING;

EID: 0029894951     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(95)01000-9     Document Type: Article

References (38)

1. Bush TL, Barret-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1106-1109.
2. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47-63.
3. Inman WHW, Vessey MP, Westerholm B, Englund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 1970; 2: 203-209.
4. Meade TW. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol 1988; 158: 1642-1652.
5. Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1456.
6. Isacson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent 'idiophatic' venous thrombosis. Acta Chir Scand 1972; 138: 313.
7. Hedner U, Nilsson IM. Antithrombin III in a clinical material. Thromb Res 1973; 3: 631-641.
8. Marlar RA, Montgomery RR, Madden RM. Homozygous protein C deficiency. In: RM Bertina ed. Protein C and related proteins. UK: Churchill Livingstone, 1988; 182-195.
9. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-1400.
10. Wiman B, Hamsten A. Correlations between fibrinolytic function and acute myocardial infarction. Am J Cardiol 1990; 66: 54G-56G.
11. Aznar J, Estellés A, Tormo G, Sapena P, Tormo V, Blanch S, España F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-541.
12. Meade TW, Brozovic M, Mellows S, Chakrabarti RR, Haines AP, Imeson JD et al. Haemostatic function and ischaemic heart disease: principal results of the Northwich Park Heart Study. Lancet 1986; ii: 533-537.
13. Wilhemsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
14. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham study. J Am Med Assoc 1987; 258: 1183-1186.
15. Lindoff C, Petersson F, Lecander I, Martinsson G, Åstedt B. Passage of the menopause is followed by haemostatic changes. Maturitas 1993; 17: 17-22.
16. Kluft C, Andreotti F. Consequences of the circadian fluctuation in plasminogen activator inhibitor 1 (PAI-1) for studies on blood fibrinolysis. Fibrinolysis 1988; 2 Suppl 2: 93-95.
17. Jacobsson K. Studies on fibrinogen. Scand J Clin Lab Invest (Suppl) 1955; 14: 7.
18. Persson I, Adami H-O, Lindberg S, Johansson EDB, Manell P. Practice and patterns of oestrogen treatment in climacteric women in a Swedish population. Acta Obstet Gynecol Scand 1983; 62: 289-296.
19. Notelovitz M, Kitchens CS, Rappaport V, Coone L, Dougherty M. Menopausal status associated with increased inhibition of blood coagulation. Am J Obstet Gynecol 1981; 141: 149-152.
20. Boston Collaborative Drug Surveillance Program. Boston University Medical Center. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal oestrogen therapy. N Engl J Med 1974; 290: 15-19.
21. Balleisen L, Bailey J, Epping P-H, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII, and fibrinogen in an industrial population-I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using and menopause. Thromb Haemostasis 1985; 54: 475-479.
22. Handa K, Kono S, Saku K, Sasaki J, Kawano T, Sasaki Y et al. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 1989; 77: 209-213.
23. Schneidau A, Harrison MJG, Hurst C, Wilkes HC, Meade TW. Arterial disease risk factors and angiographic evidence of atheroma of the carotid artery. Stroke 1989; 20: 1466-1471.
24. Wangh LJ, Hollands LJ, Spolski RS, Aprison BS, Weisel JW. Xenopus fibrinogen: characterization of subunits and hormonal regulation of biosynthesis. J Biol Chem 1983; 258: 4599-4605.
25. Lee AJ, Lowe G, Smith W, Tunstall-Pedoe H. Plasma fibrinogen: its relationship with oral contraception, the menopause, and hormone replacement therapy. Clin Biochemistry 1992; 25: 403-405.
26. Nabulsi AA, Folsom AR, White A, Patsch Att ventilen öppnar sig., Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-1075.
27. Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 1986; 15: 355-370.
28. Kannel W, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: The Framingham study. Ann Intern Med 1976; 85: 447-452.
29. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
30. Grülich-Henn J, Müller-Berghaus G. The role of vascular endothelial cells in the regulation of fibrinolysis. Z Kardiol 1989; 78: 25-29.
31. Hashimoto Y, Kolayashi A, Yamazaki N, Suguwara Y, Takada Y, Takada A. Relationship between age and plasma t-PA, PA-inhibitor and PA activity. Thromb Res 1987; 46: 625-633.
32. Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of oestradiol valerate and low dose ethinyl oestradiol on haemostasis parameters. Thromb Haemostasis 1989; 61: 65-69.
33. Caine GY, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemostasis 1992; 68 (4): 392-395.
34. Fox J, George J, Newton JR, Parsons AD, Stuart GK, Stuart J, Sturdee DW. Effect of transdermal oestradiol on the haemostatic balance of menopausal women. Maturitas 1993; 18: 55-64.
35. Nichols KC, Schenkel L, Benson H. 17β-oestradiol for postmenopausal oestrogen replacement therapy. Obstet Gynecol Surv 1984; 39: 230-245.
36. Bush TL, Cowan LD, Barett-Connor E, Criqui MH, Karon JM, Wallace RB et al. Estrogen use and all-cause mortality. J Am Med Assoc 1983; 249: 903-906.
37. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; i: 858-860.
38. Basdevant A, de Lignieres B, Simon P, Blache D, Ponsin G, Guy-Grand B. Hepatic lipase activity during oral and parenteral 17β-oestradiol replacement therapy: high-density lipoprotein increase may not be antiatherogenic. Fertil Steril 1991; 55: 1112-1117.